title: Subconjunctival bevacizumab for corneal neovascularization secondary to topical anesthetic abuse.
abstract: We report the clinical course of a 56-year-old patient diagnosed with toxic keratopathy due to topical anesthetic abuse. One month later, while a large corneal epithelial defect persisted, the cornea developed circumferential neovascularization that was treated with subconjunctival bevacizumab. Corneal neovascularization (CN) showed a dramatic regression 1 week after subconjunctival injection of bevacizumab. The epithelial defect slowly healed, no complications were observed, and no recurrence observed after 4 months of follow-up. In conclusion, bevacizumab may be valid complementary treatment in patients with CN secondary to topical anesthetic abuse. To our knowledge, this is the first case of CN due to topical anesthetic abuse benefiting from treatment of subconjunctival bevacizumab.
authors.affiliation: University of Patras, Medical School, Department of Ophthalmology, Patras, Greece. cgeorg@upatras.gr
authors.forename: Constantine D
authors.initials: CD
authors.lastname: Georgakopoulos
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Vasilakis
authors.forename: Olga E
authors.initials: OE
authors.lastname: Makri
authors.forename: Eleni
authors.initials: E
authors.lastname: Beredima
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Pharmakakis
mesh_terms: D000779:Anesthetics, Local / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D016510:Corneal Neovascularization / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D056965:Injections, Intraocular; D007634:Keratitis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D013748:Tetracaine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000779:Anesthetics, Local; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D009883:Ophthalmic Solutions; D013748:Tetracaine; D000068258:Bevacizumab